News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
228,420 Results
Type
Article (7172)
Company Profile (16)
Press Release (221232)
Multimedia
Podcasts (3)
Webinars (1)
Section
Business (63135)
Career Advice (295)
Deals (14768)
Drug Delivery (28)
Drug Development (36793)
Employer Resources (24)
FDA (6415)
Job Trends (4909)
News (121822)
Policy (11632)
Tag
Academia (567)
Accelerated approval (2)
Adcomms (7)
Allergies (37)
Alliances (14785)
ALS (28)
Alzheimer's disease (602)
Antibody-drug conjugate (ADC) (42)
Approvals (6462)
Artificial intelligence (107)
Autoimmune disease (10)
Automation (3)
Bankruptcy (147)
Best Places to Work (4608)
BIOSECURE Act (2)
Biosimilars (21)
Biotechnology (18)
Bladder cancer (57)
Brain cancer (15)
Breast cancer (111)
Cancer (1189)
Cardiovascular disease (71)
Career advice (259)
Career pathing (4)
CAR-T (91)
Cell therapy (223)
Cervical cancer (12)
Clinical research (31239)
Collaboration (311)
Compensation (91)
Complete response letters (7)
COVID-19 (724)
CRISPR (19)
C-suite (78)
Cystic fibrosis (37)
Data (1356)
Denatured (1)
Depression (20)
Diabetes (112)
Diagnostics (2235)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (48)
Drug pricing (41)
Drug shortages (17)
Duchenne muscular dystrophy (40)
Earnings (33379)
Editorial (15)
Employer branding (1)
Employer resources (19)
Events (31153)
Executive appointments (252)
FDA (7112)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (270)
Gene editing (48)
Generative AI (10)
Gene therapy (135)
GLP-1 (185)
Government (1254)
Grass and pollen (2)
Guidances (46)
Healthcare (6139)
Huntington's disease (5)
IgA nephropathy (16)
Immunology and inflammation (36)
Indications (17)
Infectious disease (786)
Inflammatory bowel disease (62)
Inflation Reduction Act (5)
Influenza (24)
Intellectual property (54)
Interviews (45)
IPO (8035)
IRA (17)
Job creations (571)
Job search strategy (221)
Kidney cancer (8)
Labor market (5)
Layoffs (41)
Leadership (4)
Legal (2100)
Liver cancer (41)
Lung cancer (166)
Lymphoma (85)
Machine learning (2)
Management (7)
Manufacturing (107)
MASH (39)
Medical device (4588)
Medtech (4589)
Mergers & acquisitions (7095)
Metabolic disorders (284)
Multiple sclerosis (41)
NASH (8)
Neurodegenerative disease (25)
Neuropsychiatric disorders (4)
Neuroscience (817)
NextGen: Class of 2025 (1499)
Non-profit (712)
Obesity (139)
Opinion (76)
Ovarian cancer (54)
Pain (39)
Pancreatic cancer (48)
Parkinson's disease (67)
Partnered (5)
Patents (138)
Patient recruitment (67)
Peanut (17)
People (14547)
Pharmaceutical (8)
Pharmacy benefit managers (6)
Phase I (9977)
Phase II (13743)
Phase III (10305)
Pipeline (772)
Policy (34)
Postmarket research (796)
Preclinical (3664)
Press Release (9)
Prostate cancer (53)
Psychedelics (11)
Radiopharmaceuticals (119)
Rare diseases (158)
Real estate (1004)
Recruiting (7)
Regulatory (9175)
Reports (13)
Research institute (510)
Resumes & cover letters (39)
Rett syndrome (4)
RNA editing (2)
RSV (16)
Schizophrenia (29)
Series A (44)
Series B (31)
Service/supplier (2)
Sickle cell disease (23)
Special edition (2)
Spinal muscular atrophy (31)
Sponsored (14)
Startups (675)
Stomach cancer (5)
Supply chain (26)
Tariffs (3)
The Weekly (1)
Vaccines (172)
Venture capitalists (5)
Weight loss (76)
Women's health (6)
Worklife (4)
Date
Today (7)
Last 7 days (388)
Last 30 days (1146)
Last 365 days (15742)
2025 (5046)
2024 (16923)
2023 (19100)
2022 (22235)
2021 (23636)
2020 (21798)
2019 (14442)
2018 (10639)
2017 (11456)
2016 (9543)
2015 (11737)
2014 (8103)
2013 (5877)
2012 (6042)
2011 (6749)
2010 (6222)
Location
Africa (176)
Alabama (16)
Alaska (2)
Arizona (55)
Arkansas (3)
Asia (17578)
Australia (4853)
California (2958)
Canada (1145)
China (249)
Colorado (123)
Connecticut (168)
Delaware (62)
Europe (28032)
Florida (436)
Georgia (69)
Idaho (6)
Illinois (215)
India (20)
Indiana (123)
Japan (94)
Kansas (14)
Kentucky (6)
Louisiana (5)
Maine (36)
Maryland (359)
Massachusetts (2102)
Michigan (52)
Minnesota (105)
Missouri (36)
Montana (11)
Nebraska (8)
Nevada (41)
New Hampshire (36)
New Jersey (1019)
New Mexico (3)
New York (940)
North Carolina (396)
North Dakota (2)
Northern California (1305)
Ohio (65)
Oklahoma (1)
Oregon (7)
Pennsylvania (689)
Puerto Rico (7)
Rhode Island (8)
South America (302)
South Carolina (12)
Southern California (1138)
Tennessee (42)
Texas (448)
United States (10877)
Utah (69)
Virginia (80)
Washington D.C. (18)
Washington State (345)
West Virginia (2)
Wisconsin (12)
228,420 Results for "fujitsu limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Fujitsu tackles ‘drug loss’ in Japan through ecosystem to accelerate digitalization of clinical trials
August 26, 2024
·
1 min read
Fujitsu and Baptist Health South Florida transform operating room scheduling with newly launched solution to boost utilization rates and the financial health of the surgical discipline
Fujitsu announced the launch of an innovative solution to its Uvance Healthy Living portfolio to transform surgical capacity utilization with a new approach in the market by targeting the root cause of surgical block time inefficiencies.
September 14, 2023
·
1 min read
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Press Releases
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
April 14, 2025
·
5 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
Layoffs
Pliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical Trials
Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, Pliant is paring back its workforce.
May 2, 2025
·
2 min read
·
Angela Gabriel
Press Releases
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
April 7, 2025
·
4 min read
Press Releases
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
March 13, 2025
·
3 min read
Press Releases
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
December 5, 2024
·
19 min read
Press Releases
Nemysis Limited Announces Collaboration With Avia Pharma AB as IHAT Distributor in Nordic Region
March 14, 2025
·
2 min read
1 of 22,842
Next
